Literature DB >> 2442262

Tumor-specific idiotype vaccines. III. Induction of T helper cells by anti-idiotype and tumor cells.

S Raychaudhuri, Y Saeki, J J Chen, H Kohler.   

Abstract

In a previous report, we have demonstrated the induction of tumor-specific immunity by monoclonal anti-idiotype antibodies generated against a monoclonal anti-tumor antibody, 11C1, that also cross-reacts with mouse mammary tumor virus envelope glycoprotein gp52. Also, we showed that whereas one anti-idiotype antibody, 2F10, could induce protective immunity, another anti-idiotype antibody, 3A4, induced nonprotective immunity. Here we demonstrated the existence of T helper cells which recognize anti-idiotypes that exert differential controls on tumor growth. The qualitative nature of idiotype recognizing T cells generated in response to 2F10, 3A4, irradiated tumor, and progressively growing tumor was compared. The reactivity pattern of idiotype recognizing T cells obtained from 2F10 and irradiated tumor immunized mice were similar in nature in the sense that Lyt-2- T cells obtained from these immunized mice responded to both 2F10 and 3A4 as antigen, although T cells from tumor immunized mice responded better to 3A4 antigen. On the other hand, the idiotype-recognizing T cells obtained from 3A4-immunized mice showed a similar reactivity pattern to T cells isolated from mice during the early phase of tumor growth (within day 4 to 5 after the inoculation of 10(4) live tumor cells). Lyt-2- T cells isolated from mice immunized with 3A4 or during the early phase of tumor growth responded only to 3A4 antigen. The inability of Lyt-2- T cells, isolated from 4- to 5-day-old tumor in mice, to cooperate with 2F10-TNP is not due to the absence of 2F10 idiotype recognizing T cells as 2F10 id recognizing T cells are present when examined at the precursor level. These data on the idiotype specificity of T helper cells show a correlation with the presence of anti-tumor immunity. This information will help in the design and application of idiotype vaccine in tumor immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2442262

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  3 in total

Review 1.  Idiotypic antibody immunotherapy of cancer.

Authors:  M B Chatterjee; K A Foon; H Köhler
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

2.  Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine.

Authors:  K A Foon; M Chakraborty; W J John; A Sherratt; H Köhler; M Bhattacharya-Chatterjee
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

3.  Tumor idiotype vaccines. VIII. Analysis of protective idiotype in sera and hybridomas derived from tumor-bearing mice with long-term survival.

Authors:  J J Chen; H Kohler
Journal:  Cancer Immunol Immunother       Date:  1993-11       Impact factor: 6.968

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.